Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted) (2018 - 2026)

Ocular Therapeutix has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at -$0.4 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 5.26% year-over-year to -$0.4; the TTM value through Mar 2026 reached -$1.44, down 26.32%, while the annual FY2025 figure was -$1.42, 16.39% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.4 at Ocular Therapeutix, down from -$0.27 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.22 in Q1 2022 and troughed at -$0.49 in Q1 2024.
  • A 5-year average of -$0.31 and a median of -$0.27 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 77.27% in 2023 and later increased 22.45% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.24 in 2022, then fell by 4.17% to -$0.25 in 2023, then dropped by 12.0% to -$0.28 in 2024, then grew by 3.57% to -$0.27 in 2025, then tumbled by 48.15% to -$0.4 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for OCUL at -$0.4 in Q1 2026, -$0.27 in Q4 2025, and -$0.38 in Q3 2025.